Form 4 for DYN Dyne Therapeutics, Inc.
Accepted 2025-04-01 00:00:00 ET · period of report 2025-03-31 · accession 0000950170-25-048601 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-01 | 2025-03-31 | DYN | Lucera Erick | CFO | A - Grant | $0.00 | +66.1K | 66.1K | New | $0 |
| D | 2025-04-01 | 2025-03-31 | DYN | Lucera Erick | CFO | A - Grant | $0.00 | +214.5K | 214.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-31 | A | A | 66,100 | $0.00 | 66,100 | D | — | — | (F1) Consists of shares of Common Stock issuable under 66,100 restricted stock units ("RSU"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest as to 25% of the shares in equal annual installments over four years with the first installment vesting on March 31, 2026, subject to continuous service. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-03-31 | A | A | 214,500 | $0.00 | 214,500 | D | $10.46 · — to 2035-03-30 | 214,500 Common Stock | (F2) The option was granted on March 31, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 31, 2026, and the remainder vesting in 12 equal quarterly installments thereafter, subject to continuous service. |